D-K6L9 Peptide Combination with IL-12 Inhibits the Recurrence of Tumors in Mice

Abstract

D-K6L9 peptide is bound by phosphatidylserine and induces necrosis in cancer cells. In our therapeutic experience, this peptide, when administered directly into B16-F10 murine melanoma tumors, inhibited their growth. Cessation of therapy results, however, in tumor relapse. We aimed at developing a combined therapy involving D-K6L9 and additional factors that would yield complete elimination of tumor cells in experimental animals. To this purpose, we employed glycyrrhizin, an inhibitor of HMGB1 protein, BP1 peptide and interleukin (IL)-12. Glycyrrhizin or BP1, when combined with D-K6L9, inhibits growth of primary tumors only during the period of their administration. A long-term tumor growth inhibitory effect was obtained only in combining D-K6L9 with IL-12. At 2 months following therapy cessation, 60 % of animals were alive. Prolonged survival was noted in mice bearing B16-F10 tumors as well as in mice bearing C26 colon carcinoma tumors.

A lupine (Lupinus angustifolious L.) peptide prevents non-alcoholic fatty liver disease in high-fat-diet-induced obese mice

“…Doses of 0.5 and 1 mg kg −1 day −1 of the synthesized GPETAFLR peptide were established according to previous studies [23][24][25][26][27][28] and the expected water consumption of the C57BL/6J strain. 29 These selected doses for animals were comparable to human equivalent doses (HED) of 40 and 80 µg kg −1 .…”

Antitumor activity of opiorphin, sialorphin and their conjugates with a peptide klaklakklaklak

“…However, cessation of peptide administration led to tumor regrowth. As reported in the literature, necrosis-triggering agents released from necrotic cells, among others the HMGB1 protein, induce a chronic inflammatory condition and formation of a new tumor microenvironment and angiogenesis that facilitates tumor regrowth [38].…”

Antimicrobial Peptides As Biologic and Immunotherapeutic Agents against Cancer: A Comprehensive Overview

“…D-K6L9 is a peptide is bound by phosphatidylserine which is capable of inducing tumor necrosis. Its administration to B16-F10 murine melanoma tumors inhibited its growth, whereas therapeutic cessation led to tumor relapse ( 79 ). Combinations comprising D-K6L9 with glycyrrhizin (an inhibitor of HMGB1 protein), BP1 peptide, and interleukin (IL)-12 exhibit antitumor efficacy.…”

“…Two months after therapeutic cessation, a remarkable 60% of animals remained alive. Significantly prolonged survival was observed in both mice bearing B16-F10 tumors as well as in mice bearing C26 colon carcinoma tumors ( 79 ).…”